{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:34:38Z","timestamp":1792654478411,"version":"4.5.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40265-025-02171-3","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T18:28:36Z","timestamp":1743704916000},"page":"677-693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6323-7518","authenticated-orcid":false,"given":"Qiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfu","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangbo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2461-5747","authenticated-orcid":false,"given":"Hongxing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"2171_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sc.2013.135","volume":"52","author":"M Fitzharris","year":"2014","unstructured":"Fitzharris M, Cripps RA, Lee BB. Estimating the global incidence of traumatic spinal cord injury. Spinal Cord. 2014;52:117\u201322.","journal-title":"Spinal Cord"},{"key":"2171_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/sc.2012.165","volume":"52","author":"PW New","year":"2014","unstructured":"New PW, Cripps RA, Bonne LB. Global maps of non-traumatic spinal cord injury epidemiology: towards a living data repository. Spinal Cord. 2014;52:97\u2013109.","journal-title":"Spinal Cord"},{"key":"2171_CR3","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s00345-018-2301-z","volume":"36","author":"R Hamid","year":"2018","unstructured":"Hamid R, Averbeck MA, Chiang H, Garcia A, Al Mousa RT, Oh SJ, et al. Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury. World J Urol. 2018;36:1517\u201327.","journal-title":"World J Urol"},{"key":"2171_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","volume":"18","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Nichols E, Bhutta ZA, Gebrehiwot TT, Hay SI, et al. Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:269\u201385.","journal-title":"Lancet Neurol"},{"key":"2171_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrurol.2016.53","volume":"13","author":"V Ph\u00e9","year":"2016","unstructured":"Ph\u00e9 V, Chartier-Kastler E, Panicker JN. Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol. 2016;13:275\u201388.","journal-title":"Nat Rev Urol"},{"key":"2171_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.rehab.2017.02.008","volume":"60","author":"M Przydacz","year":"2017","unstructured":"Przydacz M, Denys P, Corcos J. What do we know about neurogenic bladder prevalence and management in developing countries and emerging regions of the world? Ann Phys Rehabil Med. 2017;60:341\u20136.","journal-title":"Ann Phys Rehabil Med"},{"key":"2171_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(05)70801-1","volume":"365","author":"ZX Zhang","year":"2005","unstructured":"Zhang ZX, Roman GC, Hong Z, Wu CB, Qu QM, Huang JB, et al. Parkinson\u2019s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet. 2005;365:595\u20137.","journal-title":"Lancet"},{"key":"2171_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ucl.2017.04.001","volume":"44","author":"ID Palma-Zamora","year":"2017","unstructured":"Palma-Zamora ID, Atiemo HO. Understanding the economic impact of neurogenic lower urinary tract dysfunction. Urol Clin North Am. 2017;44:333\u201343.","journal-title":"Urol Clin North Am"},{"key":"2171_CR9","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/nau.23981","volume":"38","author":"A Jaggi","year":"2019","unstructured":"Jaggi A, Nazir J, Fatoye F, Siddiqui E, Choudhury N, Argoubi R, et al. Drug utilization patterns and healthcare resource use and costs in patients with neurogenic bladder in the United Kingdom: a retrospective primary care database study. Neurourol Urodyn. 2019;38:1278\u201389.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33:641\u201356.","journal-title":"Med Decis Making"},{"key":"2171_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac114","author":"D McClurg","year":"2022","unstructured":"McClurg D, Elders A, Hagen S, Mason H, Booth J, Cunnington A-L, et al. Stimulation of the tibial nerve\u2014a randomised trial for urinary problems associated with Parkinson\u2019s\u2014the STARTUP trial. Age Ageing. 2022. https:\/\/doi.org\/10.1093\/ageing\/afac114.","journal-title":"Age Ageing"},{"key":"2171_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104252","volume":"68","author":"MH Marzouk","year":"2022","unstructured":"Marzouk MH, Darwish MH, El-Tamawy MS, Morsy S, Abbas RL, Ali AS. Posterior tibial nerve stimulation as a neuromodulation therapy in treatment of neurogenic overactive bladder in multiple sclerosis: a prospective randomized controlled study. Mult Scler Relat Disord. 2022;68: 104252.","journal-title":"Mult Scler Relat Disord."},{"key":"2171_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.eururo.2022.03.010","volume":"82","author":"M Kennelly","year":"2022","unstructured":"Kennelly M, Cruz F, Herschorn S, Abrams P, Onem K, Solomonov VK, et al. Efficacy and safety of abobotulinumtoxina in patients with neurogenic detrusor overactivity incontinence performing regular clean intermittent catheterization: pooled results from two phase 3 randomized studies (CONTENT1 and CONTENT2). Eur Urol. 2022;82:223\u201332.","journal-title":"Eur Urol"},{"key":"2171_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.23736\/S2724-6051.21.04227-2","volume":"74","author":"A Giannantoni","year":"2022","unstructured":"Giannantoni A, Gubbiotti M, Rubilotta E, Balzarro M, Antonelli A, Bini V. IncobotulinumtoxinA versus onabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a double-blind, randomized, non-inferiority trial. Minerva Urol Nephrol. 2022;74:625\u201335.","journal-title":"Minerva Urol Nephrol."},{"key":"2171_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/21681805.2021.1990994","volume":"56","author":"M Moussa","year":"2021","unstructured":"Moussa M, Chakra MA, Dabboucy B, Fares Y, Dellis A, Papatsoris A. The safety and effectiveness of mirabegron in Parkinson\u2019s disease patients with overactive bladder: a randomized controlled trial. Scand J Urol. 2021;56:66\u201372.","journal-title":"Scand J Urol"},{"key":"2171_CR16","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/iju.14602","volume":"28","author":"M Honda","year":"2021","unstructured":"Honda M, Yokoyama O, Takahashi R, Matsuda T, Nakayama T, Mogi T. Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension. Int J Urol. 2021;28:906\u201312.","journal-title":"Int J Urol"},{"key":"2171_CR17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/nau.24552","volume":"40","author":"SY Cho","year":"2021","unstructured":"Cho SY, Jeong SJ, Lee S, Kim J, Lee SH, Choo MS, et al. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson\u2019s disease: a double-blind, randomized placebo-controlled trial (Parkinson\u2019s Disease Overactive bladder Mirabegron, PaDoMi Study). Neurourol Urodyn. 2021;40:286\u201394.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/10790268.2020.1712892","volume":"44","author":"H Chen","year":"2021","unstructured":"Chen H, Xie K, Jiang C. A single-blind randomized control trial of trigonal versus nontrigonal Botulinum toxin-A injections for patients with urinary incontinence and poor bladder compliance secondary to spinal cord injury. J Spinal Cord Med. 2021;44:757\u201364.","journal-title":"J Spinal Cord Med"},{"key":"2171_CR19","doi-asserted-by":"crossref","unstructured":"Welk B, McKibbon M. A randomized, controlled trial of transcutaneous tibial nerve stimulation to treat overactive bladder and neurogenic bladder patients. Can Urol Assoc J [Internet]. 2020;14. Available from: https:\/\/www-embase-com-443.webvpn.cams.cn\/search\/results?subaction=viewrecord&id=L2005837572&from=export.","DOI":"10.5489\/cuaj.6142"},{"key":"2171_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.euf.2019.11.008","volume":"6","author":"J Tornic","year":"2020","unstructured":"Tornic J, Liechti MD, Stalder SA, Birkh\u00e4user V, van der Lely S, Leitner L, et al. Transcutaneous tibial nerve stimulation for treating neurogenic lower urinary tract dysfunction: a pilot study for an international multicenter randomized controlled trial. Eur Urol Focus. 2020;6:909\u201315.","journal-title":"Eur Urol Focus"},{"key":"2171_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000008931","author":"C McDonald","year":"2020","unstructured":"McDonald C, Rees J, Winge K, Newton JL, Burn DJ. Bladder training for urinary tract symptoms in Parkinson disease. Neurology. 2020. https:\/\/doi.org\/10.1212\/wnl.0000000000008931.","journal-title":"Neurology"},{"key":"2171_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/0964528420925488","volume":"39","author":"H Chen","year":"2020","unstructured":"Chen H, Wang C, Zhou M, Yan Chan P, Lo Yam L, Lok Lam W, et al. Electroacupuncture for post-stroke overactive bladder: a multi-centre pilot randomized controlled trial. Acupunct Med. 2020;39:175\u201383.","journal-title":"Acupunct Med"},{"key":"2171_CR23","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/nau.24595","volume":"40","author":"TG Araujo","year":"2020","unstructured":"Araujo TG, Schmidt AP, Sanches PRS, Silva Junior DP, Rieder CRM, Ramos JGL. Transcutaneous tibial nerve home stimulation for overactive bladder in women with Parkinson\u2019s disease: a randomized clinical trial. Neurourol Urodyn. 2020;40:538\u201348.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR24","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00345-019-02981-7","volume":"38","author":"T Yonguc","year":"2019","unstructured":"Yonguc T, Sefik E, Inci I, Kusbeci OY, Celik S, Ayd\u0131n ME, et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson\u2019s disease. World J Urol. 2019;38:2013\u20139.","journal-title":"World J Urol"},{"key":"2171_CR25","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1002\/nau.24052","volume":"38","author":"CP Vaughan","year":"2019","unstructured":"Vaughan CP, Burgio Kathryn L, Goode PS, Juncos JL, McGwin G, Muirhead L, et al. Behavioral therapy for urinary symptoms in Parkinson\u2019s disease: a randomized clinical trial. Neurourol Urodyn. 2019;38:1737\u201344.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/ner.12855","volume":"22","author":"A Stampas","year":"2019","unstructured":"Stampas A, Korupolu R, Zhu L, Smith CP, Gustafson K. Safety, feasibility, and efficacy of transcutaneous tibial nerve stimulation in acute spinal cord injury neurogenic bladder: a randomized control pilot trial. Neuromodulation. 2019;22:716\u201322.","journal-title":"Neuromodulation"},{"key":"2171_CR27","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1002\/nau.23774","volume":"12","author":"B Welk","year":"2018","unstructured":"Welk B, Hickling D, McKibbon M, Radomski S, Ethans K. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2018;12:2810\u20137.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR28","doi-asserted-by":"publisher","first-page":"e657","DOI":"10.1212\/WNL.0000000000005991","volume":"91","author":"M Tullman","year":"2018","unstructured":"Tullman M, Chartier-Kastler E, Kohan A, Keppenne V, Brucker BM, Egerdie B, et al. Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS. Neurology. 2018;91:e657\u201365.","journal-title":"Neurology"},{"key":"2171_CR29","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/nau.23566","volume":"37","author":"J Krhut","year":"2018","unstructured":"Krhut J, Borovi\u010dka V, B\u00edlkov\u00e1 K, S\u00fdkora R, M\u00edka D, Mokri\u0161 J, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2018;37:2226\u201333.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013702","volume":"97","author":"G Guo","year":"2018","unstructured":"Guo G, Kang Y. Effectiveness of neuromuscular electrical stimulation therapy in patients with urinary incontinence after stroke. Medicine. 2018;97: e13702.","journal-title":"Medicine"},{"key":"2171_CR31","first-page":"eAO4207","volume":"16","author":"RS Ferreira","year":"2018","unstructured":"Ferreira RS, D\u2019Ancona CAL, Oelke M, Carneiro MR. Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial. Einstein (Sao Paulo, Brazil). 2018;16:eAO4207.","journal-title":"Einstein (Sao Paulo, Brazil)."},{"key":"2171_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/nau.22954","volume":"36","author":"P Denys","year":"2017","unstructured":"Denys P, Del Popolo G, Amarenco G, Karsenty G, Le Berre P, Padrazzi B, et al. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport\u00ae (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): a randomised placebo-controlled phase IIa study. Neurourol Urodyn. 2017;36:457\u201362.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR33","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/nau.22945","volume":"36","author":"G Amarenco","year":"2017","unstructured":"Amarenco G, Sutory M, Zachoval R, Agarwal M, Del Popolo G, Tretter R, et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourol Urodyn. 2017;36:414\u201321.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/nau.22755","volume":"35","author":"A Schr\u00f6der","year":"2016","unstructured":"Schr\u00f6der A, Albrecht U, Schnitker J, Reitz A, Stein R. Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: a randomized, prospective, controlled multi-center trial. Neurourol Urodyn. 2016;35:582\u20138.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/PHM.0000000000000360","volume":"95","author":"Y Liu","year":"2016","unstructured":"Liu Y, Xu G, Luo M, Teng H. Effects of transcutaneous electrical nerve stimulation at two frequencies on urinary incontinence in poststroke patients. Am J Phys Med Rehabil. 2016;95:183\u201393.","journal-title":"Am J Phys Med Rehabil"},{"key":"2171_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/sc.2015.143","volume":"54","author":"C Hui","year":"2016","unstructured":"Hui C, Keji X, Chonghe J, Ping T, Rubiao O, Jianweng Z, et al. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity. Spinal Cord. 2016;54:46\u201350.","journal-title":"Spinal Cord"},{"key":"2171_CR37","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.parkreldis.2015.02.025","volume":"21","author":"TA Zesiewicz","year":"2015","unstructured":"Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2015;21:514\u201320.","journal-title":"Parkinsonism Relat Disord"},{"key":"2171_CR38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/WON.0000000000000078","volume":"42","author":"MC Perissinotto","year":"2015","unstructured":"Perissinotto MC, D\u2019Ancona CAL, Lucio A, Campos RM, Abreu A. Transcutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms and its impact on health-related quality of life in patients with Parkinson disease. J Wound Ostomy Continence Nurs. 2015;42:94\u20139.","journal-title":"J Wound Ostomy Continence Nurs"},{"key":"2171_CR39","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11255-015-0911-6","volume":"47","author":"G Chen","year":"2015","unstructured":"Chen G, Liao L, Li Y. The possible role of percutaneous tibial nerve stimulation using adhesive skin surface electrodes in patients with neurogenic detrusor overactivity secondary to spinal cord injury. Int Urol Nephrol. 2015;47:451\u20135.","journal-title":"Int Urol Nephrol"},{"key":"2171_CR40","doi-asserted-by":"crossref","unstructured":"Guo Z, Liu Y, Hu G, Liu H, Xu Y. Transcutaneous electrical nerve stimulation in the treatment of patients with poststroke urinary incontinence. Clin Interv Aging. 2014;9:851\u20136.","DOI":"10.2147\/CIA.S61084"},{"key":"2171_CR41","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1159\/000350247","volume":"91","author":"V \u0160\u00e1mal","year":"2013","unstructured":"\u0160\u00e1mal V, Me\u010dl J, \u0160r\u00e1m J. Submucosal administration of onabotulinumtoxinA in the treatment of neurogenic detrusor overactivity: pilot single-centre experience and comparison with standard injection into the detrusor. Urol Int. 2013;91:423\u20138.","journal-title":"Urol Int"},{"key":"2171_CR42","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s00345-012-0984-0","volume":"31","author":"A Apostolidis","year":"2013","unstructured":"Apostolidis A, Thompson C, Yan X, Mourad S. An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. World J Urol. 2013;31:1469\u201374.","journal-title":"World J Urol"},{"key":"2171_CR43","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/sc.2012.76","volume":"50","author":"J Krhut","year":"2012","unstructured":"Krhut J, Samal V, Nemec D, Zvara P. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study. Spinal Cord. 2012;50:904\u20137.","journal-title":"Spinal Cord"},{"key":"2171_CR44","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","volume":"187","author":"D Ginsberg","year":"2012","unstructured":"Ginsberg D, Gousse A, Keppenne V, Sievert K-D, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131\u20139.","journal-title":"J Urol"},{"key":"2171_CR45","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","volume":"185","author":"S Herschorn","year":"2011","unstructured":"Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185:2229\u201335.","journal-title":"J Urol"},{"key":"2171_CR46","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60:742\u201350.","journal-title":"Eur Urol"},{"key":"2171_CR47","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.eururo.2010.06.035","volume":"58","author":"P Grise","year":"2010","unstructured":"Grise P, Ruffion A, Denys P, Egon G, Chartier KE. Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses. Eur Urol. 2010;58:759\u201366.","journal-title":"Eur Urol"},{"key":"2171_CR48","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.juro.2010.08.028","volume":"184","author":"TA Abdel-Meguid","year":"2010","unstructured":"Abdel-Meguid TA. Botulinum toxin-A injections into neurogenic overactive bladder\u2014to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol. 2010;184:2423\u20138.","journal-title":"J Urol"},{"key":"2171_CR49","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.eururo.2006.03.016","volume":"51","author":"M St\u00f6hrer","year":"2007","unstructured":"St\u00f6hrer M, M\u00fcrtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele J-J. Propiverine compared to oxybutynin in neurogenic detrusor overactivity\u2014results of a randomized, double-blind, multicenter clinical study. Eur Urol. 2007;51:235\u201342.","journal-title":"Eur Urol"},{"key":"2171_CR50","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.juro.2006.07.025","volume":"176","author":"M Lazzeri","year":"2006","unstructured":"Lazzeri M, Cal\u00f2 G, Spinelli M, Malaguti S, Guerrini R, Salvadori S, et al. Daily intravesical instillation of 1 mg nociceptin\/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study. J Urol. 2006;176:2098\u2013102.","journal-title":"J Urol"},{"key":"2171_CR51","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/nau.20296","volume":"25","author":"M De S\u00e8ze","year":"2006","unstructured":"De S\u00e8ze M, Gallien P, Denys P, Labat J-J, Serment G, Grise P, et al. Intravesical glucidic capsaicin versus glucidic solvent in neurogenic detrusor overactivity: a double blind controlled randomized study. Neurourol Urodyn. 2006;25:752\u20137.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR52","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.eururo.2005.04.012","volume":"48","author":"C Silva","year":"2005","unstructured":"Silva C, Silva J, Ribeiro M-J, Avelino A, Cruz F. Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial. Eur Urol. 2005;48:650\u20135.","journal-title":"Eur Urol"},{"key":"2171_CR53","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","volume":"174","author":"B Schurch","year":"2005","unstructured":"Schurch B, De S\u00e8ze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196\u2013200.","journal-title":"J Urol"},{"key":"2171_CR54","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/01.ju.0000132152.53532.5d","volume":"172","author":"A Giannantoni","year":"2004","unstructured":"Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol. 2004;172:240\u20133.","journal-title":"J Urol"},{"key":"2171_CR55","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/01.ju.0000100385.93801.d4","volume":"171","author":"M De S\u00e8ze","year":"2004","unstructured":"De S\u00e8ze M, Wiart L, De S\u00e8ze M-P, Soyeur L, Dosque J-P, Blajezewski S, et al. Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study. J Urol. 2004;171:251\u20135.","journal-title":"J Urol"},{"key":"2171_CR56","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0090-4295(02)02587-6","volume":"61","author":"M Lazzeri","year":"2003","unstructured":"Lazzeri M, Cal\u00f2 G, Spinelli M, Guerrini R, Salvadori S, Beneforti P, et al. Urodynamic effects of intravesical nociceptin\/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study. Urology. 2003;61:946\u201350.","journal-title":"Urology"},{"key":"2171_CR57","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1080\/10790268.2003.11753706","volume":"26","author":"JH Kim","year":"2003","unstructured":"Kim JH, Rivas DA, Shenot PJ, Green B, Kennelly M, Erickson JR, et al. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med. 2003;26:358\u201363.","journal-title":"J Spinal Cord Med"},{"key":"2171_CR58","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1097\/01.ju.0000084623.65480.f8","volume":"170","author":"P Abrams","year":"2003","unstructured":"Abrams P, Amarenco G, Bakke A, Buczy\u0144ski A, Castro-Diaz D, Harrison S, et al. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol. 2003;170:1242\u201351.","journal-title":"J Urol"},{"key":"2171_CR59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000019818","volume":"35","author":"T Yamanishi","year":"1999","unstructured":"Yamanishi T, Yasuda K, Homma Y, Kawabe K, Morita T. A multicenter placebo-controlled, double-blind trial of urapidil, an alpha-blocker, on neurogenic bladder dysfunction. Eur Urol. 1999;35:45\u201351.","journal-title":"Eur Urol"},{"key":"2171_CR60","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/sj.sc.3100750","volume":"37","author":"M St\u00f6hrer","year":"1999","unstructured":"St\u00f6hrer M, Madersbacher H, Richter R, Wehnert J, Dreikorn K. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia\u2014a double-blind, placebo-controlled clinical trial. Spinal Cord. 1999;37:196\u2013200.","journal-title":"Spinal Cord"},{"key":"2171_CR61","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/sj.sc.3100505","volume":"36","author":"L Wiart","year":"1998","unstructured":"Wiart L, Joseph PA, Petit H, Dosque JP, De S\u00e8ze M, Brochet B, et al. The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double blind placebo controlled study in patients with spinal cord disease. Preliminary results. Spinal Cord. 1998;36:95\u20139.","journal-title":"Spinal Cord"},{"key":"2171_CR62","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/(SICI)1520-6777(1998)17:5<499::AID-NAU6>3.0.CO;2-8","volume":"17","author":"PE Van Kerrebroeck","year":"1998","unstructured":"Van Kerrebroeck PE, Amarenco G, Th\u00fcroff JW, Madersbacher HG, Lock MT, Messelink EJ, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn. 1998;17:499\u2013512.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR63","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/(SICI)1520-6777(1998)17:5<513::AID-NAU7>3.0.CO;2-G","volume":"17","author":"M De S\u00e8ze","year":"1998","unstructured":"De S\u00e8ze M, Wiart L, Joseph P-A, Dosque J-P, Mazaux J-M, Barat M. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn. 1998;17:513\u201323.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR64","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1464-410X.1995.tb07264.x","volume":"75","author":"H Madersbacher","year":"1995","unstructured":"Madersbacher H, St\u00f6hrer M, Richter R, Burgd\u00f6rfer H, Hachen HJ, M\u00fcrtz G. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol. 1995;75:452\u20136.","journal-title":"Br J Urol"},{"key":"2171_CR65","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/nau.23009","volume":"36","author":"B Peyronnet","year":"2017","unstructured":"Peyronnet B, Castel-Lacanal E, Roumiguie M, Even L, Marque P, Soulie M, et al. Intradetrusor injections of onabotulinum toxin A (Botox(R)) 300 U or 200 U versus abobotulinum toxin A (Dysport(R)) 750 U in the management of neurogenic detrusor overactivity: a case control study. Neurourol Urodyn. 2017;36:734\u20139.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR66","doi-asserted-by":"publisher","unstructured":"Scaglione F. Conversion ratio between Botox\u00ae, Dysport\u00ae, and Xeomin\u00ae in clinical practice. Toxins (Basel). 2016;8(3):65. https:\/\/doi.org\/10.3390\/toxins8030065","DOI":"10.3390\/toxins8030065"},{"key":"2171_CR67","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1590\/S1677-55382006000600002","volume":"32","author":"M Lazzeri","year":"2006","unstructured":"Lazzeri M, Spinelli M. The challenge of overactive bladder therapy: alternative to antimuscarinic agents. Int Braz J Urol. 2006;32:620\u201330.","journal-title":"Int Braz J Urol"},{"key":"2171_CR68","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/nau.22571","volume":"34","author":"N Aizawa","year":"2015","unstructured":"Aizawa N, Homma Y, Igawa Y. Effects of L-arginine, mirabegron, and oxybutynin on the primary bladder afferent nerve activities synchronized with reflexic, rhythmic bladder contractions in the rat: afferent activities and bladder contractions. Neurourol Urodyn. 2015;34:368\u201374.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR69","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.urology.2004.11.021","volume":"65","author":"Y Kim","year":"2005","unstructured":"Kim Y, Yoshimura N, Masuda H, De Miguel F, Chancellor MB. agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology. 2005;65:238\u201342.","journal-title":"Urology"},{"key":"2171_CR70","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1097\/01.ju.0000138472.16876.8d","volume":"172","author":"T Oki","year":"2004","unstructured":"Oki T, Kimura R, Saito M, Miyagawa I, Yamada S. Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004;172:2059\u201364.","journal-title":"J Urol"},{"key":"2171_CR71","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/S0022-5347(05)65540-1","volume":"166","author":"S Di Stasi","year":"2001","unstructured":"Di Stasi S, Giannantoni A, Navarra P, Capelli G, Storti L, Porena M, et al. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. J Urol. 2001;166:2232\u20136.","journal-title":"J Urol"},{"key":"2171_CR72","unstructured":"Silva C, Rio Me Fau - Cruz F, Cruz F. Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia."},{"key":"2171_CR73","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.urology.2004.10.007","volume":"65","author":"A Apostolidis","year":"2005","unstructured":"Apostolidis A, Brady CM, Yiangou Y, Davis J, Fowler CJ, Anand P. Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. Urology. 2005;65:400\u20135.","journal-title":"Urology"},{"key":"2171_CR74","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/nau.23314","volume":"37","author":"V Ph\u00e9","year":"2018","unstructured":"Ph\u00e9 V, Schneider MP, Peyronnet B, Abo Youssef N, Mordasini L, Chartier-Kastler E, et al. Intravesical vanilloids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS). Neurourol Urodyn. 2018;37:67\u201382.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR75","doi-asserted-by":"crossref","unstructured":"Lazzeri M, Spinelli M, Zanollo A, Turini D. Intravesical vanilloids and neurogenic incontinence: ten years experience. Urol Int. 2004;72:145\u20139.","DOI":"10.1159\/000075969"},{"key":"2171_CR76","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/164_2018_182","volume":"254","author":"P Angelico","year":"2019","unstructured":"Angelico P, Barchielli M, Lazzeri M, Guerrini R, Cal\u00f3 G. Nociceptin\/orphanin FQ and urinary bladder. Handb Exp Pharmacol. 2019;254:347\u201365.","journal-title":"Handb Exp Pharmacol"},{"key":"2171_CR77","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/nau.22797","volume":"35","author":"A Apostolidis","year":"2016","unstructured":"Apostolidis A, Rahnama\u2019i MS, Fry C, Dmochowski R, Sahai A. Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014. Neurourol Urodyn. 2016;35:293\u20138.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR78","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","volume":"49","author":"A Apostolidis","year":"2006","unstructured":"Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006;49:644\u201350.","journal-title":"Eur Urol"},{"key":"2171_CR79","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jfma.2018.02.002","volume":"118","author":"SF Chen","year":"2019","unstructured":"Chen SF, Jiang YH, Kuo HC. Single onabotulinumtoxinA 200U dose improved clinical symptoms but not urothelial dysfunction in neurogenic detrusor overactivity due to spinal cord injury. J Formos Med Assoc. 2019;118:125\u201333.","journal-title":"J Formos Med Assoc"},{"key":"2171_CR80","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.purol.2015.07.006","volume":"25","author":"B Peyronnet","year":"2015","unstructured":"Peyronnet B, Sanson S, Amarenco G, Castel-Lacanal E, Chartier-Kastler E, Charvier K, et al. Definition of botulinum toxin failure in neurogenic detrusor overactivity: preliminary results of the DETOX survey. Progres en urologie journal de l\u2019Association francaise d\u2019urologie et de la Societe francaise d\u2019urologie. 2015;25:1219\u201324.","journal-title":"Progres en urologie journal de l\u2019Association francaise d\u2019urologie et de la Societe francaise d\u2019urologie."},{"key":"2171_CR81","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.juro.2015.05.077","volume":"194","author":"K Spradling","year":"2015","unstructured":"Spradling K, Khoyilar C, Abedi G, Okhunov Z, Wikenheiser J, Yoon R, et al. Redefining the autonomic nerve distribution of the bladder using 3-dimensional image reconstruction. J Urol. 2015;194:1661\u20137.","journal-title":"J Urol"},{"key":"2171_CR82","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s11255-021-02802-0","volume":"53","author":"J Ton","year":"2021","unstructured":"Ton J, Downing P, Versi E, van Uem S, Ephraim S, Murphy M, et al. Outcomes of a single trigone-only vs. 20 trigone-sparing injections of OnabotulinumtoxinA for refractory overactive bladder (OAB). Int Urol Nephrol. 2021;53:1067\u201372.","journal-title":"Int Urol Nephrol"},{"key":"2171_CR83","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.eururo.2011.10.043","volume":"61","author":"RP Manecksha","year":"2012","unstructured":"Manecksha RP, Cullen IM, Ahmad S, McNeill G, Flynn R, McDermott TE, et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol. 2012;61:928\u201335.","journal-title":"Eur Urol"},{"key":"2171_CR84","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.eururo.2010.02.031","volume":"58","author":"R Pinto","year":"2010","unstructured":"Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome\/interstitial cystitis. Eur Urol. 2010;58:360\u20135.","journal-title":"Eur Urol"},{"key":"2171_CR85","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/nau.23475","volume":"37","author":"YH Jiang","year":"2018","unstructured":"Jiang YH, Jhang JF, Lee CL, Kuo HC. Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment-A prospective, randomized, clinical trial. Neurourol Urodyn. 2018;37:1467\u201373.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR86","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/nau.21054","volume":"30","author":"HC Kuo","year":"2011","unstructured":"Kuo HC. Bladder base\/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn. 2011;30:1242\u20138.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR87","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.juro.2006.10.047","volume":"177","author":"G Karsenty","year":"2007","unstructured":"Karsenty G, Elzayat E, Delapparent T, St-Denis B, Lemieux MC, Corcos J. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol. 2007;177:1011\u20134.","journal-title":"J Urol"},{"key":"2171_CR88","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","volume":"178","author":"HC Kuo","year":"2007","unstructured":"Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol. 2007;178:1359\u201363.","journal-title":"J Urol"},{"key":"2171_CR89","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00345-011-0736-6","volume":"30","author":"SH Alloussi","year":"2012","unstructured":"Alloussi SH, Lang C, Eichel R, Al-Kaabneh A, Seibold J, Schwentner C, et al. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment. World J Urol. 2012;30:367\u201373.","journal-title":"World J Urol"},{"key":"2171_CR90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/nau.20515","volume":"27","author":"F Mascarenhas","year":"2008","unstructured":"Mascarenhas F, Cocuzza M, Gomes CM, Le\u00e3o N. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. Neurourol Urodyn. 2008;27:311\u20134.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR91","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/sj.sc.3101736","volume":"43","author":"K De Laet","year":"2005","unstructured":"De Laet K, Wyndaele JJ. Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord. 2005;43:397\u20139.","journal-title":"Spinal Cord"},{"key":"2171_CR92","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00345-008-0362-0","volume":"27","author":"U Mehnert","year":"2009","unstructured":"Mehnert U, Boy S, Schmid M, Reitz A, von Hessling A, Hodler J, et al. A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol. 2009;27:397\u2013403.","journal-title":"World J Urol"},{"key":"2171_CR93","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/nau.22395","volume":"33","author":"Y-C Chen","year":"2014","unstructured":"Chen Y-C, Kuo H-C. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients. Neurourol Urodyn. 2014;33:129\u201334.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR94","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/nau.22934","volume":"36","author":"M Kennelly","year":"2017","unstructured":"Kennelly M, Dmochowski R, Schulte-Baukloh H, Ethans K, Del Popolo G, Moore C, et al. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: final results of a long-term extension study. Neurourol Urodyn. 2017;36:368\u201375.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR95","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.juro.2016.04.046","volume":"196","author":"E Rovner","year":"2016","unstructured":"Rovner E, Kohan A, Chartier-Kastler E, Junemann KP, Del Popolo G, Herschorn S, et al. Long-term efficacy and safety of onabotulinumtoxina in patients with neurogenic detrusor overactivity who completed 4 years of treatment. The J Urol. 2016;196:801\u20138.","journal-title":"The J Urol."},{"key":"2171_CR96","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.eururo.2012.02.036","volume":"62","author":"P Madhuvrata","year":"2012","unstructured":"Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol. 2012;62:816\u201330.","journal-title":"Eur Urol"},{"key":"2171_CR97","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/luts.12315","volume":"12","author":"A Kennedy","year":"2020","unstructured":"Kennedy A, Christie A, Malik RD, Zimmern PE. Contemporary use of prescription medications for neurogenic lower urinary tract dysfunction. LUTS. 2020;12:266\u201373.","journal-title":"LUTS"},{"key":"2171_CR98","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/01.phm.0000219229.92056.c2","volume":"85","author":"MB Chancellor","year":"2006","unstructured":"Chancellor MB, Anderson RU, Boone TB. Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil. 2006;85:536\u201345.","journal-title":"Am J Phys Med Rehabil"},{"key":"2171_CR99","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0022-5347(01)68161-8","volume":"158","author":"YH Kim","year":"1997","unstructured":"Kim YH, Bird ET, Priebe M, Boone TB. The role of oxybutynin in spinal cord injured patients with indwelling catheters. J Urol. 1997;158:2083\u20136.","journal-title":"J Urol"},{"key":"2171_CR100","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/sc.2015.195","volume":"54","author":"J W\u00f6llner","year":"2016","unstructured":"W\u00f6llner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new \u03b2-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54:78\u201382.","journal-title":"Spinal Cord"},{"key":"2171_CR101","doi-asserted-by":"crossref","first-page":"117","DOI":"10.21037\/tau.2016.07.02","volume":"5","author":"MT Sanford","year":"2016","unstructured":"Sanford MT, Suskind AM. Neuromodulation in neurogenic bladder. Transl Androl Urol. 2016;5:117\u201326.","journal-title":"Transl Androl Urol."},{"key":"2171_CR102","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/nau.1930050404","volume":"5","author":"DB Vodusek","year":"2010","unstructured":"Vodusek DB, Light JK, Libby JM. Detrusor inhibition induced by stimulation of pudendal nerve afferents. Neurourol Urodyn. 2010;5:381\u20139.","journal-title":"Neurourol Urodyn"},{"key":"2171_CR103","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.eururo.2015.07.001","volume":"68","author":"MP Schneider","year":"2015","unstructured":"Schneider MP, Gross T, Bachmann LM, Blok BFM, Castro-Diaz D, Del Popolo G, et al. Tibial nerve stimulation for treating neurogenic lower urinary tract dysfunction: a systematic review. Eur Urol. 2015;68:859\u201367.","journal-title":"Eur Urol"},{"key":"2171_CR104","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.juro.2013.02.034","volume":"190","author":"UJ Barroso","year":"2013","unstructured":"Barroso UJ, Viterbo W, Bittencourt J, Farias T, Lord\u00ealo P. Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children. J Urol. 2013;190:673\u20137.","journal-title":"J Urol"},{"key":"2171_CR105","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S1474-4422(15)00070-8","volume":"14","author":"JN Panicker","year":"2015","unstructured":"Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 2015;14:720\u201332.","journal-title":"Lancet Neurol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02171-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02171-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02171-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:02:50Z","timestamp":1745575370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02171-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":105,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2171"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02171-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"25 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for conducting this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Qiang Wang, Canyong Li, Yongfu Long, Bin Cao, Yangbo Lu, Gang Luo, Yaqiang Huang, Guiyan Huang, and Hongxing Huang declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"QW and HXH conceived the study. QW, CYL and HXH designed the study protocol. YFL, GYH and QW performed the literature searches. QW, CYL, YFL, BC, YBL and GYH were involved in study identification and data acquisition. QW and YFL performed the statistical analysis. QW wrote the draft of the manuscript. QW, CYL, YFL, BC, YBL, YQH, GL and HXH critical revised the manuscript for important intellectual content. HXH, GL and YQH supervised the study.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}